Strategic Partnerships CrystecPharma has recently announced a strategic partnership with Joel Hi-Tech, presenting an opportunity to position joint offerings that leverage mSAS technology for accelerated development programs and co-sell with a broader tech ecosystem.

Industry Recognition Key leadership and team members have received industry awards and recognition, including Future Leader finalist and Women in Pharma accolades, which can be leveraged to open doors with premium customers seeking proven innovation and strong execution.

Clinical & Biotech Focus The company specializes in stabilisation of biotech-derived therapeutics and polymorph screening, enabling partnerships with biotech firms seeking robust formulation and stability solutions for biologics or complex small molecules.

Global Event Presence Regular participation in major events like CPHI and BIO International Convention signals active market engagement; use these touchpoints to coordinate targeted outreach, demonstrations of mSAS capabilities, and introductory meetings with attendees.

Solubility & Delivery Needs CrystecPharma’s focus on improving dissolution, bioavailability, and alternative delivery routes (including inhalation and taste masking) aligns with pharmaceutical companies facing solubility-limited pipelines or reformulation needs, offering upsell opportunities for early-stage to late-stage projects.